Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Profound Medical Corp.TSX: PRN.TO

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures outflow grows to $0

Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$179.08K.

Context

  • Capital expenditures amounted to 1.1% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Capital expenditures increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$44.77K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$179.08K— YoY
LTMMar 2026
-$179.08K— YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(179.08K) USD
Year-over-year change
—

Capital Expenditures vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Capital expenditures amounts to 1.0% of revenue for PRN.TO, versus a peer median of 2.0%.
PRN.TO Competitors
Capital Expenditures for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$5.72M USD-6.0%-9.6%1.9%
CRRX.TOCareRx CorporationLTM Mar 2026CA$4.61M CAD-36.2%-25.7%1.2%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$3.26M CAD+29.2%-35.1%2.1%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$1.78M USD+5138.8%-72.6%3.2%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$727.56K USD+188.2%+24.8%—
PRN.TOProfound Medical Corp.LTM Mar 2026$179.08K USD——1.0%
Peer median (excluding PRN.TO) —+29.2%-25.7%2.0%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.7M)(28.67M)(28.32M)(27.82M)(42.57M)
Depreciation & Amortization1.88M1.6M1.15M936K569.8K
Deferred Income Tax(293K)0232K00
Stock-Based Compensation7.21M4.24M3.42M2.58M5.49M
Change in Working Capital(877K)(5.63M)540K591K(1.74M)
Accounts Receivables2M(1.93M)(1.41M)186K(175.01K)
Inventory(2.49M)(1.86M)353K656K(2.87M)
Accounts Payables(356K)(566K)1.36M815K384.62K
Other Working Capital(26K)(1.27M)244K(1.07M)918.81K
Other Non-Cash Items425K2.66M379K255K(622.65K)
Operating Cash Flow(22.36M)(25.8M)(22.61M)(23.45M)(38.88M)
Capital Expenditures(593K)000(179.08K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(583.04K)000(246.24K)
Debt Repayment(386K)6.92M(1.2M)(2.56M)(1.33M)
Common Stock Issued6.32M255.17K2.71M62.11M43.19M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.03K(141.17K)248.74K(4.85M)0
Financing Cash Flow5.95M7.03M1.76M54.7M41.86M
Effect of Forex Changes244K(1.87M)549K(2.54M)(630.95K)
Net Change in Cash(16.76M)(20.64M)(20.3M)28.7M2.11M
Free Cash Flow(22.95M)(25.8M)(22.3M)(23.45M)(39.05M)

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.